- BNF:
- Immune system and malignant disease
- Status:
- Red
- Decision Date:
- July 2016
Comments
RED:
- NICE TA395: for previously treated anaplastic lymphoma kinase positive non-small cell lung cancer. (Decision date - July 2016).
- NICE TA500: for untreated ALK- positive non-small cell lung cancer. (Decision date - February 2018).
NHS England drug. To be used in line with NHSE commissioning intentions.
Red Drug Classifications
- 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
- 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
search again